Placebo Sample Clauses

Placebo. Sponsor shall be responsible for the Manufacture and supply of placebo, comparator products and diagnostic products, in each case, as applicable and to the extent set forth in the applicable Study Plan; provided that, except as otherwise set forth in a Study Plan, Regeneron shall be responsible for the Manufacture and supply of placebo and diagnostic products for the Regeneron Product. The provisions of this Article 9 applicable to the supply of Product shall also apply to any such placebo or comparator product.

Placebo. During this study there is a XX chance that you will receive a placebo. HIV Testing: Research procedures include testing for HIV. For studies that involve Whole Genome Sequencing (WGS): Make clear in the consent form that WGS will be included as a research procedure. Include a description of WGS such as; WGS is the sequencing of a human germline or somatic biospecimen with the intent to generate the complete DNA sequence of that biospecimen.

Placebo. Provide matching placebo in sufficient quantities to supply MGH throughout the course of the Regimen Study. Packaging and labeling is the responsibility of MGH’s ALS Platform Trial Central Pharmacy vendor unless otherwise determined by the Company. Company shall ship drug directly to MGH’s ALS Platform Trial’s Central Pharmacy vendor for distribution to Study Sites in an appropriately temperature-controlled manner as specified by the Company.

Placebo. Minimal dose Low dose Medium dose High dose

Placebo. Placebo is provided as a preservative-free, colorless aqueous solution containing the same excipients as TNX-1900, minus oxytocin. Administration instructions are identical to those for TNX-1900. Intranasal application bottles containing placebo will deliver 0.10 mL volume per spray. A dose of placebo will comprise 1 spray per nostril (2 sprays total). A brief training on placebo response will be given to patients at Visits V1, V2, V3, V4, and V5.

Placebo. During this study you could receive placebo. This could lengthen the amount of time before you receive a treatment that may be effective. During this time you may experience worsening of your condition, including increased symptoms such as [XX]. The researchers will carefully monitor your condition. If your symptoms worsen and make you uncomfortable, you can withdraw from the study. Blood draw: Removing blood by a needle may cause temporary pain, bruising, bleeding, swelling, dizziness, and on rare instances fainting or infection. Exercise testing: The exercise test may cause muscle soreness, dizziness, or shortness of breath. In rare instances, exercise tests may cause chest pain, tightness, or a change in ▇▇▇▇▇ ▇▇▇▇▇. Psychological discomforts: Some of the procedures may cause embarrassment or anxiety, or the questions the researchers ask you may be upsetting or make you uncomfortable. If you do not wish to answer a question, you can skip it and go to the next question. If you do not wish to participate you can stop. HIV testing: Being tested for HIV may make you feel nervous or anxious about the test results. A positive test indicates that you have been infected with the HIV virus, but no one knows for certain when, if ever, you will become sick with AIDS or a related condition. Receiving positive results may make you very upset. If other people learn about your positive test results, you may have trouble obtaining insurance or employment. To the extent permitted by law, the researchers will keep your test results confidential and will not release them to anyone without your written permission. If you test positive, California law requires health care providers and clinical laboratories to report the HIV test results with your personal identifying information to the local health department.

Placebo. Placebo vials matching the single-dose vials of IPP-201101 will be supplied by ImmuPharma. Each vial contains a white to off-white, amorphous powder as a lyophilized sterile formulation of mannitol (and acetic acid used for pH adjustment, if necessary). Before reconstitution, vials of placebo must be stored under refrigerated conditions (2° to 8° C [36° to 46° F]) in a secure place and protected from light. The study center will receive box(es) with up to 13 vials per box. Each vial will be labeled with a 4-digit treatment number and each box will contain placebo vials. Prior to administration, placebo should be reconstituted with 1.1 mL sterile water for injection (volume of injection of 1.1 mL). After reconstitution, the vial can be stored at controlled room temperature (20° to 25° C [68° to 77° F]) for up to 2 hours prior to administration and does not need to be protected from light. Patients randomly assigned to placebo will be administered placebo sc every 4 weeks for 48 weeks (a total of 13 doses will be administered). Method of Blinding: Patients will be randomly assigned to treatment through a qualified randomization service provider (eg, interactive response technology [IRT]). Patients and investigators will remain blinded to treatment assignment during the study. Study drug may not be administered by the same individual performing the SLEDAI- 2K, BILAG-2004, or PhGA. Study drug should be administered at each study visit after all study visit procedures and assessments have been completed.

Placebo. Placebos (in appropriate studies) will be manufactured using the same excipients as the active tablets. Premix comprised of [**] and [**]. Additional inactive excipients: microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate are blended with [**] to match active tablets. All excipients used in the manufacture of the placebo tablets are of compendial grade and/or pharmaceutical quality. None of the excipients used in the manufacture of the drug product are novel or have animal or human origin.

Placebo. A placebo tablet is available which conforms to the appearance, shape and size of the TVB-2640 50-mg strength tablet.